Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures SAN CARLOS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of […]
Tag: BioCardia
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the […]
BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 2,038,836 shares of its common stock at a […]
BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase […]
BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal […]
BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems
SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company’s proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy […]
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report […]
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA](“BioCardia” or the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the publication of data from […]
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
Technology May Enable Same-Day Outpatient Cell Therapy Procedures SAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of U.S. Patent No: 10,780,248 for […]
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet